Voyager Therapeutics Company Insiders
| VYGR Stock | USD 5.75 0.06 1.05% |
Voyager Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Voyager Therapeutics suggests that virtually all insiders are panicking. Voyager Therapeutics employs about 162 people. The company is managed by 13 executives with a total tenure of roughly 11 years, averaging almost 0.0 years of service per executive, having 12.46 employees per reported executive.
| Andre Turenne CEO President CEO |
| Robert Hesslein President Senior Vice President General Counsel |
Voyager Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-10-02 | Sandell Jacquelyn Fahey | Disposed 5999 @ 5.82 | View | ||
| 2024-01-17 | Todd Alfred Carter | Disposed 1266 @ 7.18 | View |
Monitoring Voyager Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Voyager |
Voyager Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Voyager Therapeutics' future performance. Based on our forecasts, it is anticipated that Voyager will maintain a workforce of slightly above 160 employees by January 2025.Voyager Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of 0.0157 % which means that it generated a profit of $0.0157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1022 %, meaning that it created $0.1022 on every $100 dollars invested by stockholders. Voyager Therapeutics' management efficiency ratios could be used to measure how well Voyager Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Voyager Therapeutics Workforce Comparison
Voyager Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,009. Voyager Therapeutics holds roughly 162 in number of employees claiming about 8% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.56) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.56. Voyager Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Voyager Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Voyager Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Voyager Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.0 | 1 | 1 | 80,000 | 5,999 |
| 2024-06-01 | 5.0 | 10 | 2 | 321,000 | 13,472 |
| 2024-03-01 | 1.5714 | 11 | 7 | 1,048,500 | 28,539 |
| 2023-12-01 | 1.0 | 1 | 1 | 61,000 | 13,567 |
| 2023-09-01 | 0.6667 | 2 | 3 | 127,000 | 21,000 |
| 2023-06-01 | 2.75 | 11 | 4 | 247,000 | 18,696 |
| 2023-03-01 | 0.44 | 11 | 25 | 5,179,588 | 3,174,985 |
| 2022-09-01 | 0.4 | 2 | 5 | 88,000 | 487,667 |
| 2022-06-01 | 5.0 | 10 | 2 | 653,400 | 4,313 |
| 2022-03-01 | 1.0833 | 13 | 12 | 2,562,705 | 212,781 |
| 2021-12-01 | 0.4286 | 3 | 7 | 41,563 | 54,360 |
| 2021-06-01 | 9.0 | 9 | 1 | 285,292 | 3,516 |
| 2021-03-01 | 2.0 | 12 | 6 | 770,000 | 31,209 |
| 2020-06-01 | 3.5 | 7 | 2 | 105,000 | 6,591 |
| 2020-03-01 | 2.6667 | 8 | 3 | 498,750 | 17,557 |
| 2018-09-01 | 2.0 | 4 | 2 | 661,000 | 3,000,000 |
| 2018-06-01 | 1.4 | 7 | 5 | 105,000 | 3,057,451 |
| 2018-03-01 | 0.45 | 9 | 20 | 418,416 | 152,233 |
| 2017-09-01 | 0.3333 | 1 | 3 | 250,000 | 21,960 |
| 2017-06-01 | 1.75 | 7 | 4 | 105,000 | 1,840,000 |
| 2017-03-01 | 2.0 | 4 | 2 | 514,000 | 108,459 |
| 2016-03-01 | 2.0 | 4 | 2 | 275,000 | 29,745 |
| 2015-12-01 | 0.2778 | 5 | 18 | 24,124,999 | 113,319,407 |
Voyager Therapeutics Notable Stakeholders
A Voyager Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Voyager Therapeutics often face trade-offs trying to please all of them. Voyager Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Voyager Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Guangping Gao | Founder Board | Profile | |
| Phillip Zamore | Founder Board | Profile | |
| Trista Morrison | Chief CEO | Profile | |
| Andre Turenne | President CEO | Profile | |
| Robert Hesslein | Senior Vice President General Counsel | Profile | |
| Sandrock MD | CEO Pres | Profile | |
| Dr MBA | Chief Officer | Profile | |
| JD Esq | Chief Officer | Profile | |
| Todd Carter | Chief Officer | Profile | |
| Robin Swartz | Chief Officer | Profile | |
| Krystof MD | Founder | Profile | |
| Peter CPA | Chief Officer | Profile | |
| Michelle Smith | Chief Officer | Profile |
About Voyager Therapeutics Management Performance
The success or failure of an entity such as Voyager Therapeutics often depends on how effective the management is. Voyager Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Voyager management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Voyager management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.
Voyager Therapeutics Workforce Analysis
Traditionally, organizations such as Voyager Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Voyager Therapeutics within its industry.Voyager Therapeutics Manpower Efficiency
Return on Voyager Therapeutics Manpower
| Revenue Per Employee | 1.5M | |
| Revenue Per Executive | 19.2M | |
| Net Income Per Employee | 816.9K | |
| Net Income Per Executive | 10.2M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 19.6M |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.